Skip to content

Released Feb 4, 2025, before the open

10-K filed Feb 27, 2025, 58 days after period end · 0000078003-25-000054

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$17.76Bderived+199.5% vs Q4 2023+0.3% vs Q3 2024
Net Income$410.00MderivedN/M vs Q4 2023−90.8% vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived$6,721,000,000+28.3%
Free Cash Flowderived$5,804,000,000+38.3%
Margins · derived
Net margin2.3%+59.1 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$17.76B$5.93B$15.75B$16.19B
Net Income$410.00M-$3.37B$4.99B$3.39B

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR